TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
TransMedics Group (TMDX) PT Lowered to $125 at Oppenheimer
October 29, 2024 6:04 AM EDTOppenheimer analyst Suraj Kalia lowered the price target on TransMedics Group (NASDAQ: TMDX) to $125.00 (from $200.00) while maintaining a Outperform rating.
The analyst comments "TransMedics reported 3Q24 revs. of $108.8M, below our/consensus $117.1M/$115.0M estimates. In Q3, our calculated US transplant shares were 21%/27%/4%... More
